Accustem Sciences INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
AccuStem Sciences reported increased net losses in Q3 2025, driven by higher R&D and administrative costs, while actively seeking new equity financing to address critical liquidity concerns.
OQB
AccuStem Sciences, Inc. reported increased losses and a significant going concern risk, necessitating immediate additional financing to continue operations.
OQB
AccuStem Sciences reports a net loss for Q1 2025 while advancing the commercialization of its MSC lung test and StemPrintER breast cancer test.
OQB
AccuStem Sciences reports a net loss of $1.13 million for the nine months ended September 30, 2024, and acknowledges the need for additional financing to continue operations.
OQB
AccuStem Sciences reported a net loss for the second quarter of 2024 and highlighted ongoing efforts to commercialize its StemPrintER test while facing significant funding challenges.
OQB
AccuStem Sciences reported a net loss of $526,602 for the first quarter of 2024 and highlighted the need for additional financing to continue operations.